If you have been reading about WADA Prohibited List and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-27. Numbers and descriptions here follow the published literature rather than marketing material.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
The Russell 3000 is a stock market index tracking the stock performance of the 3,000 largest companies listed on stock exchanges in the United States. It is maintained by FTSE Russell and its components are determined via strict rules-based methodology, with an annual rebalancing in late June, the only time new entrants are added to the index. The index is a public-float-weighted/capitalization-weighted index. The index includes approximately 98% of the total market capitalization of U.S. public companies, with an aggregate market capitalization of about $75.6 trillion as of April 30, 2026. As of April 30, 2026, the median market capitalization of the components of the index is $2.8 billion and components range in market capitalization from $146 million to $4.8 trillion. Products linked to the Russell 3000 include index funds (exchange-traded funds and mutual funds) as well as derivatives (options and futures contracts), which are available for trading in many countries with the goal of replicating the performance of the index. Also available are modified index funds; they replicate the performance of the index with modifications such as the use of covered call strategies, equal weighting, performance buffers, leverage, inclusion of only growth or value stocks, or exclusion of certain sectors, all with the goal of changing the risk/return and yield.
== Clinical significance == It has been shown that low levels of glutathione peroxidase as measured in the serum may be a contributing factor to vitiligo. Lower plasma glutathione peroxide levels were also observed in patients with type 2 diabetes with macroalbuminuria and this was correlated to the stage of diabetic nephropathy. In one study, the activity of glutathione peroxidase along with other antioxidant enzymes such as superoxide dismutase and catalase was not associated with coronary heart disease risk in women. Glutathione peroxidase activity was found to be much lower in patients with relapsing-remitting multiple sclerosis. One study has suggested that glutathione peroxidase and superoxide dismutase polymorphisms play a role in the development of celiac disease. The activity of this enzyme has been reported to be decreased in case of copper deficiency in the liver and plasma.
The very large incentives given to pharmaceutical companies to produce orphan drugs have led to the impression that the financial support afforded to make these drugs possible is akin to abuse. Because drugs can be used to treat multiple conditions, companies can take drugs that were filed with their government agency as orphan drugs to receive financial assistance, and then market it to a wide population to increase their profit margin. For example AstraZeneca's cholesterol drug Crestor was filed as a treatment for the rare disease pediatric familial hypercholesterolemia. After the drug was approved for orphan drug designation, and AstraZeneca had received tax breaks and other advantages, AstraZeneca later applied and received FDA approval for the drug to be used to treat cholesterol in all diabetics.
===== Mass Spectrometry ===== Mass spectrometry methods are unable to determine the folding of nascent polypeptides. No current methods examine the folding states of nascent polypeptides globally in the cell. There are methods for examining the folding state of individual nascent polypeptides. One method uses a nonspecific protease to cleave the nascent peptide at a low temperature. The protease can cleave the unfolded, flexible regions, but cannot cut tightly folded regions. The products of the cleavage can then be separated and studied to determine the folded regions of the nascent peptide.
New supply chains have developed involving cluster formation; development of specialized wholesalers; leading farmers organizing supply, and farmer associations or cooperatives. In some cases supermarkets have organized their own procurement from small farmers; in others wholesale markets have adapted to meet supermarket needs.
Sources: en.wikipedia.org
== Applications == Pumps that use oil either as their working fluid (diffusion pumps), or as their lubricant (mechanical rotary pumps), are often the sources of contamination in vacuum systems. Placing a cold trap at the mouth of such a pump greatly lowers the risk that oil vapours will backstream into the cavity. Cold traps can also be used for experiments involving vacuum lines such as small-scale very low temperature distillations/condensations. This is accomplished through the use of a coolant such as liquid nitrogen or a freezing mixture of dry ice in acetone or a similar solvent with a low melting point. Liquid nitrogen is only used when dry ice or other cryogenic approaches will not condense the desired gasses since liquid nitrogen will also condense oxygen. Any oxygen gas content in the vacuum line or any leak in the vacuum line will result in liquid oxygen mixed with the target vapors, often with explosive results. When performed on a larger scale, this technique is called freeze-drying, and the cold trap is referred to as the condenser. Cold traps are also used in cryopump systems to generate hard vacua by condensing the major constituents of the atmosphere (nitrogen, oxygen, carbon dioxide and water) into their liquid or solid forms. An igloo or other snow bivouac may exploit the same principle – confinement of denser cool air within an impermeable lower volume – to reduce cold air reaching the occupants through use of a sump or cill around a raised sleeping platform within.
Ayahuasca is a South American psychoactive decoction prepared from Banisteriopsis caapi vine and a dimethyltryptamine (DMT)-containing plant, used by Indigenous cultures in the Amazon and Orinoco basins as part of traditional medicine and shamanism. The word ayahuasca, originating from Quechuan languages spoken in the Andes, refers both to the B. caapi vine and the psychoactive brew made from it, with its name meaning 'spirit rope' or 'liana of the soul'. Although often portrayed as ancient, ayahuasca likely spread across the western Amazon only within the past few centuries; the first clear written accounts appear in the 17th century. The specific ritual use of ayahuasca was widespread among Indigenous groups by the 19th century. Ayahuasca is traditionally prepared by macerating and boiling B. caapi with other plants like Psychotria viridis during a ritualistic, multi-day process. Ayahuasca has been used in diverse South American cultures for spiritual, social, and medicinal purposes, often guided by shamans in ceremonial contexts involving specific dietary and ritual practices, with the Shipibo-Konibo people playing a significant historical and cultural role in its use. Originally confined to regions of Peru, Brazil, Colombia, and Ecuador, ayahuasca became widespread in Brazil, expanding widely by the mid-20th century through syncretic religions in Brazil.
== Professor of Pathology and Head of Department Chronology == The Professor of Pathology is an established (statutory) chair at the University of Cambridge which was established in 1883. Traditionally, the Professor of Pathology was also the formal Head of department. However, in 2023 Professor Adrian Liston was elected to the Professor of Pathology while Professor Heike Laman was elected 10th Head of department and became the first woman to take on the role since the founding of the department in 1883.
The Red Savina pepper is a cultivar of the habanero chili (Capsicum chinense Jacquin), which has been selectively bred to produce spicier, heavier, and larger fruit, ultimately more potent than its derivative. Frank Garcia of GNS Spices, in Walnut, California, is credited as the developer of the Red Savina, but the exact methodology that Garcia used to select the hottest breeding strains is not publicly known.
Sources: en.wikipedia.org
== Further reading == Ordoñez-Araque, Roberto; Quishpillo-Miranda, Nadine; Ramos-Guerrero, Luis (2022). "Edible Insects for Humans and Animals: Nutritional Composition and an Option for Mitigating Environmental Damage". Insects. 13 (10): 944. doi:10.3390/insects13100944. PMC 9604210. PMID 36292894. Lange, Klaus W.; Nakamura, Yukiko (2023). "Potential contribution of edible insects to sustainable consumption and production". Frontiers in Sustainability. 4 1112950. Bibcode:2023FrSus...412950L. doi:10.3389/frsus.2023.1112950. Baiano, Antonietta (2020). "Edible insects: An overview on nutritional characteristics, safety, farming, production technologies, regulatory framework, and socio-economic and ethical implications". Trends in Food Science and Technology. 100: 35–50. doi:10.1016/j.tifs.2020.03.040. Ordoñez-Araque, Roberto; Egas-Montenegro, Erika (2021). "Edible insects: A food alternative for the sustainable development of the planet". International Journal of Gastronomy and Food Science. 23 100304. doi:10.1016/j.ijgfs.2021.100304. Li, Mengjiao; Mao, Chengjuan; Li, Xin; Jiang, Lei; Zhang, Wen; Li, Mengying; Liu, Huixue; Fang, Yaowei; Liu, Shu; Yang, Guang; Hou, Xiaoyue (2023). "Edible Insects: A New Sustainable Nutritional Resource Worth Promoting". Foods. 12 (22): 4073. doi:10.3390/foods12224073. PMC 10670618. PMID 38002131. Tang, Chufei; Yang, Ding; Liao, Huaijian; Sun, Hongwu; Liu, Chuanjing; Wei, Lanjun; Li, Fanfan (2019). "Edible insects as a food source: a review". Food Production, Processing and Nutrition. 1 8. doi:10.1186/s43014-019-0008-1.
=== Reproduction and lifespan === Breeding season takes place between August and December. The coastal taipan is oviparous, laying a clutch of 7 to 20 eggs. The eggs take 60 to 80 days to hatch, with the newly hatched snakes ranging from 30 to 34 cm (12 to 13 in) in length. The young grow quickly, averaging 6.7 cm (2.6 in) a month, and reaching a length of 1.0 m (3.3 ft) in a year. Male coastal taipans reach sexual maturity when they reach 80 cm in length, which they reach around 16 months of age, while females are able to breed when they are around 100 cm long, around 28 months old.
Abdul Basit, senior associate fellow at the International Centre for Political Violence and Terrorism Research (ICPVTR), stressed that the concern was not the drones' sophistication, but their presence in Pakistan's capital. Taliban drones forced airspace closures and targeted deep within the country, escalating the threat both horizontally and vertically. Hammad Waleed, a research associate at Pakistan's Strategic Vision Institute, stated that while Pakistan's air defense could counter numbered drone projectiles, it would struggle against drone swarms.
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.